Rhino-orbital mucormycosis in a Mexican patient with COVID-19: Case report

Palabras clave

SARS-CoV-2; Invasive fungal infections; PostCOVID-19 mucormycosis

Cómo citar

Gálvez Romeo, J. L., Perea-Peña, A., Huerta-Jurado, P., Parra-Salazar, M. A., Tepalcingo-Aguilar, L. M., Ramírez-Sandoval, M. P., Gijón-Mitre, R., Navarro-Alvarado, R., Hernández-Moreno, L. L., Barradas-Arroyo, D., Coronado-Cervántes, B., Rodríguez- Serrano, J. A., & Baños-Lara, M. del R. (2023). Rhino-orbital mucormycosis in a Mexican patient with COVID-19: Case report. Revista Alergia México, 69(2), 93–97. https://doi.org/10.29262/ram.v69i2.1185


Recibido 2022-11-03
Aceptado 2022-11-16
Publicado 2023-02-07


Background: A variety of bacterial and fungal co-infections may be attributed to the coronavirus disease 2019 (COVID-19), particularly in people who already have a medical condition such diabetes mellitus or those who received large dosages of steroids.

Case report: We described a 52-year-old diabetic man who was receiving high doses of dexamethasone and antibiotics while receiving ambulatory care for COVID-19 pneumonia. His anterior rhinoscopy revealed a necrotic scab, and a sample confirmed Mucor spp. He underwent surgery and was given amphotericin as a result of the severity of the condition, palpebral ptosis, and right ocular palsy he was experiencing. The patien´s progression was satisfactory. 

Conclusions: pre-existing diabetes mellitus, previous steroid and antimicrobial use, as well as SARS-CoV-2 infection are some of the risk factors associated with Mucor spp. infection. Prompt detection of mucormycosis is important in the management of these affected patients.



Mekonnen ZK, Ashraf DC, Jankowski T, Grob SR, Vagefi MR, Kersten RC, et al. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthal Plast Reconstr Surg. 2021;37(2):e40.

García LAC. Experiencia de mucormicosis en el Hospital Juárez de México. Rev Hosp Juárez México. 2017;71(1):3-13.

Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: epidemiology, diagnosis, and outcomes of reported cases. Med Mycol. 2018;56(1):29-43.

Quiroz, N., Villanueva, J. del P., & Lozano, E. A. (2017). Mucormycosis. Journal of the Colombian Association of Dermatology and Dermatological Surgery, 25(4), 284–293. https://doi.org/10.29176/2590843X.302

Hernández JL, Buckley CJ. Mucormycosis. En: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [citado 3 de mayo de 2022]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK544364/

Liu M, Spellberg B, Phan QT, Fu Y, Fu Y, Lee AS, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest. 2010;120(6):1914-24.

Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556-69.

Bonifaz A, Tirado-Sánchez A, Hernández-Medel ML, Araiza J, Kassack JJ, del Angel-Arenas T, et al. Mucormycosis at a tertiary-care center in Mexico. A 35-year retrospective study of 214 cases. Mycoses. 2021;64(4):372-80.

Camps R. The treatment of mucormycosis (zygomycosis) in the 21st century. Rev Iberoam Micol. 2018;35(4):217-21.

Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13:236–301.

Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SC, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-21.

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.

Derechos de autor 2023 Revista Alergia México


Cargando métricas ...